Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. At $71.05, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.5%; Concentration risk — Product: REDEMPLO.
Arrowhead Pharmaceuticals develops RNAi therapeutics using its proprietary TRiM platform to silence disease-causing genes, with 18 clinical-stage drug candidates. It achieved its first commercial launch in 2025 with REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome.... Read more
Sell if holding. At $71.05, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.5%; Concentration risk — Product: REDEMPLO. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Score 5.5/10, moderate confidence.
Passes 3/6 gates (clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductREDEMPLO10-K Item 1A: 'Our prospects substantially depend on the success of our clinical-stage product candidates...or successfully commercialize REDEMPLO, our business could be materially harmed.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $71.05, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.5%; Concentration risk — Product: REDEMPLO. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Prior stop was $65.81. Score 5.5/10, moderate confidence.
Take-profit target: $73.24 (+3.5% upside). Prior stop was $65.81. Stop-loss: $65.81.
Concentration risk — Product: REDEMPLO; Thin upside margin: 3.5%; Leverage penalty (D/E 1.2): -0.5.
Arrowhead Pharmaceuticals, Inc. trades at a P/E of 44.1 (forward -15.6). TrendMatrix value score: 3.9/10. Verdict: Sell.
19 analysts cover ARWR with a consensus score of 4.0/5. Average price target: $84.
What does Arrowhead Pharmaceuticals, Inc. do?Arrowhead Pharmaceuticals develops RNAi therapeutics using its proprietary TRiM platform to silence disease-causing...
Arrowhead Pharmaceuticals develops RNAi therapeutics using its proprietary TRiM platform to silence disease-causing genes, with 18 clinical-stage drug candidates. It achieved its first commercial launch in 2025 with REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome. Multiple programs are licensed to partners including Sarepta, Amgen, Takeda, GSK, and Novartis.